Massachusetts General Hospital will use a New Haven biotechnology company’s experimental agitation drug to treat symptoms of “ICU delirium” in critically ill patients hospitalized with COVID-19.
BioXcel Therapeutics says that doctors at the hospital will have access to the company’s drug, BXCL501, for “compassionate use” under the U.S. Food & Drug Administration’s expanded access program.